AZD3293

AZD3293
Names
Systematic IUPAC name
4-Methoxy-5''-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazole]-4''-amine
Other names
LY3314814
Identifiers
3D model (Jmol) Interactive image
ChemSpider 34980767
Properties
C26H28N4O
Molar mass 412.54 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

AZD3293, also known as LY3314814 is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor. A BACE inhibitor in theory would prevent the buildup of beta-amyloid and may help slow or stop Alzheimer's disease.

In September 2014 AstraZeneca and Eli Lilly and Company announced an agreement to codevelop AZD3293.[1] A pivotal Phase II/III clinical trial of AZD3293 started in late 2014 and is planned to recruit 2,200 patients and end in June 2019.[2] In April 2016 the company announced it would advance to phase 3 without modification.[3]

See also

References


This article is issued from Wikipedia - version of the 9/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.